Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C

Journal of Gastroenterology

Volumn 46, Issue 4, 2011, Pages 545-555

  Chayama, Kazuaki ^a   Hayes, C Nelson ^a   Yoshioka, Kentaro ^b   Moriwaki, Hisataka ^c   Okanoue, Takashi ^d   Sakisaka, Shotaro ^e   Takehara, Tetsuo ^f   Oketani, Makoto ^g   Toyota, Joji ^h   Izumi, Namiki ⁱ   Hiasa, Yoichi ^j   Matsumoto, Akihiro ^k   Nomura, Hideyuki ^l   Seike, Masataka ^m   Ueno, Yoshiyuki ⁿ   Yotsuyanagi, Hiroshi ^o   Kumada, Hiromitsu ^p  

^a HIROSHIMA UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^e FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g KAGOSHIMA UNIVERSITY   (Japan)

^h Sapporo Kosei General Hospital   (Japan)

ⁱ MUSASHINO RED CROSS HOSPITAL   (Japan)

^j EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l Shin Kokura Hospital   (Japan)

^m OITA UNIVERSITY   (Japan)

ⁿ TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^o UNIVERSITY OF TOKYO   (Japan)

^p TORANOMON HOSPITAL   (Japan)

more..

Author keywords

Cart analysis; Core protein; Decision tree; ISDR; LDL cholesterol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; CORE PROTEIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE DISTRIBUTION; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG RESPONSE; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; JAPAN; LEUKOCYTE COUNT; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS TITRATION;

ADULT; AGE FACTORS; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DATA MINING; DECISION TREES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RIBAVIRIN; SENSITIVITY AND SPECIFICITY; SEX FACTORS; TIME FACTORS; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 79959834050     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0358-6     Document Type: Article

References (39)

1. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26:15S-20S.
2. Di Bisceglie AM. Hepatitis C. Lancet. 1998;351:351-5.
3. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31(Suppl 1):9-16.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65. (Pubitemid 32913521)
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-55.
7. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandao-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009;150:528-40.
8. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086-97.
9. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451-60. (Pubitemid 44142452)
10. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology. 2007;46:1688-94.
11. Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology. 2010;138:503-12. 12 e1.
12. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007;46:403-10. (Pubitemid 46185701)
13. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol. 2006;78:83-90. (Pubitemid 41783847)
14. Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol. 2009;44:952-63.
15. Mori N, Imamura M, Kawakami Y, Saneto H, Kawaoka T, Takaki S, et al. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J Med Virol. 2009;81:640-9.
16. Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, et al. Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino acid 70 in the core region. Intervirology. 2010;53:105-10.
17. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol. 2009;81:452-8.
18. Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol. 2002;76:11079-90. (Pubitemid 35176224)
19. Jenke AC, Moser S, Orth V, Zilbauer M, Gerner P, Wirth S. Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy. J Viral Hepat. 2009;16:853-9.
20. Layden-Almer JE, Kuiken C, Ribeiro RM, Kunstman KJ, Perelson AS, Layden TJ, et al. Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients. J Infect Dis. 2005;192:1078-87. (Pubitemid 41266807)
21. Vuillermoz I, Khattab E, Sablon E, Ottevaere I, Durantel D, Vieux C, et al. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. J Med Virol. 2004;74:41-53. (Pubitemid 38988858)
22. Puig-Basagoiti F, Forns X, Furcic I, Ampurdanes S, Gimenez- Barcons M, Franco S, et al. Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J Gen Virol. 2005;86:1067-75. (Pubitemid 40485664)
23. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev. 2007;20:23-38. (Pubitemid 46167766)
24. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology. 2008;48:38-47. (Pubitemid 351975529)
25. El-Shamy A, Sasayama M, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, et al. Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pretreatment sera. Microbiol Immunol. 2007;51:471-82. (Pubitemid 46641684)
26. Yang SS, Lai MY, Chen DS, Chen GH, Kao JH. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. Liver Int. 2003;23:426-33.
27. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis - diagnosis, grading and staging. Hepatology. 1994;19:1513-20. (Pubitemid 24166476)
28. Chayama K, Suzuki F, Tsubota A, Akuta N, Someya T, Kobayashi M, et al. Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype. J Virol Methods. 2001;95:33-45. (Pubitemid 32493835)
29. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A. 1990;87:9524-8. (Pubitemid 120016475)
30. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis-C virus 1b - sensitivity to interferon is conferred by amino-acid substitutions in the NS5A region. J Clin Invest. 1995;96:224-30.
31. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77-81. (Pubitemid 26017933)
32. Hall M, Frank E, HolmesG, Pfahringer B, Reutemann P, Witten IH. The WEKA data mining software: an update. SIGKDD Explor. 2009;11:10-8.
33. Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009;16:75-90.
34. Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. 2010;52:1201-7.
35. Farnik H, Lange CM, Sarrazin C, Kronenberger B, Zeuzem S, Herrmann E. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol. 2010;8:884-90.
36. Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, et al. Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatol Res. 2010;40:135-44.
37. Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res. 2010;40:251-60.
38. El Malki HO, El Mejdoubi Y, Souadka A, Mohsine R, Ifrine L, Abouqal R, et al. Predictive model of biliocystic communication in liver hydatid cysts using classification and regression tree analysis. BMC Surg. 2010;10:16.
39. Augustin S, Muntaner L, Altamirano JT, Gonzalez A, Saperas E, Dot J, et al. Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis. Clin Gastroenterol Hepatol. 2009;7:1347-54.